Insulin glargine doesn't affect cancer rate in diabetes

06/27/2013 | MedPage Today (free registration) · Healio

Insulin glargine did not increase the incidence of cancer in patients with prediabetes and diabetes, researchers reported at the ADA 73rd Scientific Sessions. Data showed the rate of cancer was 1.32 per 100 person-years in the glargine and standard care groups at six years, while the unadjusted rates of cancer-related mortality were 0.54 per 100 person-years in the standard group and 0.51 per 100 person-years in the glargine group.

View Full Article in:

MedPage Today (free registration) · Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL